Zembrace® SymTouch® is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: Use only if a clear diagnosis of migraine has been established. Not indicated for the preventive treatment of migraine.

Zembrace® SymTouch® is contraindicated in patients with a history of hemiplegic or basilar migraine. This is not the only contraindication for Zembrace® SymTouch®.

Different treatment for different patients

When to prescribe

Zembrace® SymTouch® for free*

The Access Pathways® Program is a best-in-class savings and support program. Access Pathways®, in partnership with Blink Pharmacy Plus, offers:

Eligible patients pay $0* per prescription, per month, renewable annually

Fast, free home delivery

Dedicated customer support to guide you and your patients through the process

Committed to providing more

Upsher-Smith Laboratories, LLC takes pride in providing attentive customer service, having strong industry relationships and being dedicated to uninterrupted supply.

Zembrace® SymTouch® continues our commitment to ensure you have a variety of medication options that can address the unique needs of migraine patients.

References:

  1. Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: July 2019.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276